Mirae Asset Global Investments Co. Ltd. Buys 6,296 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,116 shares of the biopharmaceutical company’s stock after purchasing an additional 6,296 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.07% of Dynavax Technologies worth $1,218,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AE Wealth Management LLC bought a new position in shares of Dynavax Technologies in the 3rd quarter worth about $527,000. SG Americas Securities LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $1,112,000. State of Alaska Department of Revenue grew its position in shares of Dynavax Technologies by 1.4% during the 3rd quarter. State of Alaska Department of Revenue now owns 79,735 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 1,111 shares during the period. Ziegler Capital Management LLC bought a new stake in shares of Dynavax Technologies in the 3rd quarter valued at $317,000. Finally, Mach 1 Financial Group LLC bought a new position in Dynavax Technologies during the third quarter worth $524,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

DVAX opened at $11.84 on Tuesday. The firm’s fifty day moving average price is $12.31 and its two-hundred day moving average price is $13.26. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -197.30 and a beta of 1.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies Co. has a 1 year low of $10.06 and a 1 year high of $15.15.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DVAX. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

Insider Buying and Selling

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.98% of the stock is owned by corporate insiders.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.